Production / Operations Routine +

Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation

Medexus Confirms Cash Flow Accretion as GRAFAPEX Commercialization Accelerates

By The Northwire Desk — AI Analysis Apr 15, 2026 · 17:31 MDP · 4.03 MEDEXUS PHARMACEUTICALS INC. J

Executive Summary

Medexus Pharmaceuticals provided an operational update on the US commercialization of GRAFAPEX (treosulfan) for Injection, reporting growth in formulary inclusions and product orders at transplant centers.
Formulary inclusions increased to 56 institutions (31% of 180 US transplant centers), up from 26% as of December 31, 2025.
Product orders reached 64 of the 180 US transplant centers, up from 55 as of December 31, 2025.
Management reaffirmed expectations that annual product-level net revenue from GRAFAPEX will exceed $100 million within five years of its commercial launch.
The company expects GRAFAPEX to be accretive to quarterly operating cash flows starting in fiscal Q4 2026 (calendar Q1 2026), confirming previous guidance.
Capital structure simplification was completed: repurchased 710,100 shares under NCIB for C$2.1 million and all outstanding warrants from the October 2023 offering expired or were exercised.
No warrants to purchase common shares remain outstanding as of April 6, 2026.

Material Impact

The news confirms previously disclosed expectations regarding cash flow accretion timing (FY26 Q4/Calendar Q1 2026) rather than introducing a surprise acceleration or delay.
Commercial progress (formulary and orders) is incremental but positive, showing steady adoption without indicating a sudden spike in demand that would materially alter revenue models immediately.
The removal of all outstanding warrants eliminates future dilution risk from the October 2023 offering, which is a structural improvement but was anticipated given the expiration date.
Share repurchases ($1.5M USD / C$2.1M CAD) are modest relative to the company's cash position and do not represent a major capital allocation shift compared to the credit facility announced in November 2025.
The market reaction (price rising from ~$3.12 on March 31 to $4.06 by April 14) suggests expectations were already priced in prior to this release, making the news routine confirmation rather than a catalyst for new valuation expansion.

MDP · Price

Company Overview

Company: Medexus Pharmaceuticals Inc., a commercial-stage pharmaceutical company focused on oncology and transplant medicine.
Flagship Project: GRAFAPEX (treosulfan) for Injection, launched in the US in February 2025. It is indicated for conditioning regimens prior to hematopoietic stem cell transplantation.
Development Status: Commercialization phase in the US; seeking formulary inclusion at transplant centers.
Other Products: Rupall (Canada), Rasuvo, IXINITY, Trecondyv. Rupall faces generic erosion; GRAFAPEX is the primary growth driver.

More from MEDEXUS PHARMACEUTICALS INC. J